探讨T淋巴细胞亚群CD3⁺、CD4⁺、CD8⁺ 和CD4⁺/CD8⁺比值水平在胃癌患者外周血中的表达及意义。

采用血液分析仪技术,检测40例胃癌手术前患者(按临床分期为Ⅰ~Ⅱ级组18例,Ⅲ~Ⅳ级组22例)及25名正常对照组外周血CD3⁺、CD4⁺、CD8⁺ 细胞和CD4⁺/CD8⁺比值T细胞水平。

胃癌患者外周血CD3⁺、CD4⁺细胞、CD4⁺/CD8⁺ 比值分别为0.78%±0.35%、0.37%±0.21%、0.61%±0.42%,明显低于正常对照组(P<0.05);胃癌 Ⅲ~Ⅳ级 组CD3⁺、CD4⁺细胞 CD4⁺/CD8⁺ 比值分别为0.42%±0.27%、0.21%±0.17%、0.29%±0.25%, 明显低于Ⅰ~Ⅱ级组(0.95%±0.35%、0.45%±0.19%、0.76%±0.30%,P<0.05)。

检测胃癌患者手术前外周血CD3⁺、CD4⁺、CD8⁺细胞和CD4⁺/CD8⁺比值T细胞水平,可以初步评估胃癌患者机体免疫状态,也为肿瘤的免疫增强治疗提供了理论依据。

To investigate the clinical significance and expression of peripheral blood T lymphocyte subset CD3⁺,CD4⁺, CD8⁺ and CD4⁺/CD8⁺ ratio in patients with gastric cancer.

Peripheral blood T lymphocyte subset CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ ratio were determined by automatic blood cell analyzer in 40 patients with gastric cancer [according to the clinical stages:Ⅰ-Ⅱ stage group (18 cases) and Ⅲ-Ⅳ stage group (22 cases)] and 25 healthy subjects.

The peripheral blood T lymphocyte subset CD3⁺, CD4⁺ and CD4⁺/CD8⁺ ratio in the gastric cancer group were 0.78%±0.35%,0.37%±0.21% and 0.61%±0.42%, respectively, which were significantly lower than those in the healthy control group (P<0.05). The T lymphocyte subset CD3⁺, CD4⁺ and CD4⁺/CD8⁺ ratio in Ⅲ-Ⅳ stage group were 0.42%±0.27%,0.21%±0.17% and 0.29%±0.25%, which were significantly lower than those in Ⅰ-Ⅱ stage group(0.95%±0.35%,0.45%±0.19% and 0.76%±0.30%,P<0.05).

The determinations of T lymphocyte subset CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ ratio in peripheral blood of patients with gastric cancer are helpful to study and assess the immune status of patients , but also provide a theoretical reference to improve tumor immune therapy .